Evidence map›Paper›PMID 40361143›Full record

ArticleBMC medical informatics and decision making2025

Optimizing unsupervised feature engineering and classification pipelines for differentiated thyroid cancer recurrence prediction.

Emmanuel Onah, Uche Jude Eze, Abdullahi Salahudeen Abdulraheem, Ugochukwu Gabriel Ezigbo, Kosisochi Chinwendu Amorha, Fidele Ntie-Kang

Abstract read
In one paragraph

Article in BMC medical informatics and decision making, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Emmanuel OnahDepartment of Pharmaceutical and Medicinal Chemistry, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, 410001, Nigeria. emmanuel.onah.187260@unn.edu.ng.
Uche Jude EzeCollege of Pharmacy, Ohio State University, Ohio, 43210, USA. eze.18@buckeyemail.osu.edu.
Abdullahi Salahudeen AbdulraheemDepartment of Pharmacognosy, Faculty of Pharmacy, University of Lagos, Akoka, Yaba, Lagos, 101017, Nigeria.
Ugochukwu Gabriel EzigboSchool of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15261, USA.
Kosisochi Chinwendu AmorhaDepartment of Clinical Pharmacy and Pharmacy Management, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, 410001, Nigeria.
Fidele Ntie-KangCenter for Drug Discovery (UB-CeDD), Faculty of Science, University of Buea, Buea, Cameroon. fidele.ntie-kang@ubuea.cm.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferentiated thyroid cancer (DTC) is a common endocrine malignancy with rising incidence and frequent recurrence, despite a generally favorable prognosis. Accurate recurrence prediction is critical for guiding post-treatment strategies. This study aimed to enhance predictive performance by refining feature engineering and evaluating a diverse ensemble of machine learning models using the UCI DTC dataset.

methodsUnsupervised data engineering-specifically dimensionality reduction and clustering-was used to improve feature quality. Principal Component Analysis (PCA) and Truncated Singular Value Decomposition (t-SVD) were selected based on superior clustering metrics: adjusted Rand Index (ARI > 0.55) and V-measure (> 0.45). These were integrated into classification pipelines using Logistic Regression (LR), Support Vector Machine (SVM), Random Forest (RF), K-Nearest Neighbors (KNN), Feedforward Neural Network (FNN), and Gradient Boosting (GB). Model performance was evaluated through bootstrapping on an independent test set, stratified 10-fold cross-validation (CV), and subgroup analyses. Metrics included balanced accuracy, F1 score, AUC, sensitivity, specificity, and precision, each reported with 95% confidence intervals (CIs). SHAP analysis supported model interpretability.

resultsThe PCA-based LR pipeline achieved the best test set performance: balanced accuracy of 0.95 (95% CI: 0.90-0.99), AUC of 0.99 (95% CI: 0.97-1.00), and sensitivity of 0.94 (95% CI: 0.84-1.00). In stratified CV, it maintained strong results (balanced accuracy: 0.86; AUC: 0.97; sensitivity: 0.80), with consistent performance across clinically relevant subgroups. The t-SVD-based LR pipeline showed comparable performance on both test and CV sets. SVM and FNN pipelines also performed robustly (test AUCs > 0.99; CV AUCs > 0.96). RF and KNN had high specificity but slightly lower sensitivity (test: ~0.87; CV: 0.77-0.80). GB pipelines showed the lowest overall performance (test balanced accuracy: 0.86-0.88; CV: 0.85-0.88).

conclusionsDimensionality reduction via PCA and t-SVD significantly improved model performance, particularly for LR, SVM, FNN, RF and KNN classifiers. The PCA-based LR pipeline showed the best generalizability, supporting its potential integration into clinical decision-support tools for personalized DTC management. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

Machine LearningNeoplasm Recurrence, LocalThyroid NeoplasmsUnsupervised Machine LearningAdultFemaleHumansMaleMiddle AgedNeural Networks, ComputerBootstrappingCross-validationDifferentiated thyroid cancer (DTC)Dimensionality reductionLogistic regressionMachine learningPCARecurrence predictionSHAP analysis

Identifiers

PMID40361143
PMCPMC12070754

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.